Abstract Views :324 |
PDF Views:0
Authors
Affiliations
1 Department of Chemistry, College of Science, Mosul University, IQ
2 Department of Chemistry, College of
Science, AL Mustasiyriah University, IQ
3 Chemistry and Biochemistry, College of Medicine, AL Mustasiyriah University, IQ
Source
Medico-Legal Update, Vol 20, No 1 (2020), Pagination: 1097-1102
Abstract
Zinc deficiency in Crohn’s disease (CD)is considered a frequent finding and may exacerbate CD activity. We aimed to assess the prevalence of zinc deficiency in CD patients in clinical remission, its association with meprin and to analyze a potential impact on future disease course. Proper history with blood samples were collected from (30) healthy control group, (30) Crohn’s disease patients have been respond to biological therapy ( infliximab IFX) (response group) and (30) CD patients with (non-response group) to biological therapy undergoing surgical intervention for the estimation of zinc concentration and meprin activity. This study demonstrate a significant decrease in both zinc and meprin levels between (non- response group) and control group (p< 0.01). Similarly , zinc and meprin levels were decreased significantly ( p< 0.01) in (non- response) group as compared with re sponse group. While there were no differences between control and CD patients that have been treated with infliximab only. Meprin α is a zinc metalloproteinase, and therefore a deficiency of zinc may result in a decrease of meprin level or activity. Thus, we should maintain the balance between the meprin α that is affected by the zinc concentration then may affect the Crohn disease.
Keywords
Zinc, Crohn’s disease, Infliximab, meprin α
